NYSE:CHE - Chemed Stock Price, Forecast & News

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed declared a quarterly dividend on Friday, November 1st. Shareholders of record on Monday, November 11th will be paid a dividend of $0.32 per share on Monday, December 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date is Thursday, November 7th. View Chemed's Dividend History.

Chemed announced that its Board of Directors has initiated a share buyback program on Wednesday, March 7th 2018, which allows the company to repurchase $150,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company's board of directors believes its shares are undervalued.

Chemed Co. (NYSE:CHE) posted its quarterly earnings data on Tuesday, October, 29th. The company reported $3.46 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $3.31 by $0.15. The company had revenue of $480.61 million for the quarter, compared to the consensus estimate of $478.89 million. Chemed had a return on equity of 35.06% and a net margin of 11.14%. Chemed's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.07 EPS. View Chemed's Earnings History.

Chemed is scheduled to release their next quarterly earnings announcement on Monday, April 27th 2020. View Earnings Estimates for Chemed.

4 analysts have issued 1 year price targets for Chemed's stock. Their forecasts range from $405.00 to $500.00. On average, they anticipate Chemed's share price to reach $466.25 in the next year. This suggests that the stock has a possible downside of 5.2%. View Analyst Price Targets for Chemed.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chemed.

News articles about CHE stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Chemed earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the stock's share price in the next several days. View News Stories for Chemed.

Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include Home Depot (HD), Altria Group (MO), AT&T (T), AbbVie (ABBV), CVS Health (CVS), Chevron (CVX), Walt Disney (DIS), Enterprise Products Partners (EPD), Occidental Petroleum (OXY) and Boeing (BA).

Chemed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (3.26%), FMR LLC (2.83%), State Street Corp (2.49%), Riverbridge Partners LLC (2.29%), Investec Asset Management LTD (1.70%) and Renaissance Technologies LLC (1.23%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Institutional Ownership Trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Russell Investments Group Ltd., Barclays PLC, State Street Corp, Goldman Sachs Group Inc., Prudential Financial Inc., State of Tennessee Treasury Department and Smith Asset Management Group LP. Company insiders that have sold Chemed company stock in the last year include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Insider Buying and Selling for Chemed.

CHE stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Teacher Retirement System of Texas, Loomis Sayles & Co. L P, Marshall Wace North America L.P., Investec Asset Management LTD, Thrivent Financial for Lutherans and Bank of America Corp DE. Company insiders that have bought Chemed stock in the last two years include Donald E Saunders and George J Walsh III. View Insider Buying and Selling for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $491.69.

Chemed has a market capitalization of $7.87 billion and generates $1.78 billion in revenue each year. The company earns $205.54 million in net income (profit) each year or $11.93 on an earnings per share basis. Chemed employs 15,707 workers across the globe.View Additional Information About Chemed.

The official website for Chemed is http://www.chemed.com/.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.